Entrada Raises $59M to Advance Program to Treat Rare, Deadly Mitochondrial Disease
News
Entrada Therapeutics has raised $59 million in Series A financing to advance its intracellular enzyme replacement therapy program for treatment of a rare and deadly mitochondrial disease. Series A financing ... Read more